Glargine blood biotransformation: in vitro appraisal with human insulin immunoassay
- 30 June 2007
- journal article
- Published by Elsevier BV in Diabetes & Metabolism
- Vol. 33 (3), 205-212
- https://doi.org/10.1016/j.diabet.2006.12.002
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Subcutaneous insulin: pharmacokinetic variability and glycemic variabilityDiabetes & Metabolism, 2005
- Reproducibility and variability in the action of injected insulinDiabetes & Metabolism, 2005
- Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 DiabetesDiabetes, 2004
- Comparison of the Subcutaneous Absorption of Insulin Glargine (Lantus®) and NPH Insulin in Patients with Type 2 DiabetesHormone and Metabolic Research, 2003
- Insulin glargine: A systematic review of a long-acting insulin analogueClinical Therapeutics, 2003
- Biotransformation of insulin glargine after subcutaneous injection in healthy subjectsCurrent Medical Research and Opinion, 2003
- An overview of insulin glargineDiabetes/Metabolism Research and Reviews, 2002
- Recombinant DNA Technology in the Treatment of Diabetes: Insulin AnalogsEndocrine Reviews, 2001
- Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.Diabetes, 2000
- Assays for Insulin, Proinsulin(S) and C-PeptideAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 1999